enGene Therapeutics (ENGN) Operating Leases (2024 - 2026)
enGene Therapeutics (ENGN) posted quarterly Operating Leases of $6.0 million for Q2 2026, up 346.18% year-over-year from $1.3 million in Q2 2025, and down 4.19% quarter-over-quarter from $6.2 million in Q1 2026.
enGene Therapeutics (ENGN) Operating Leases (2024 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Operating Leases for 3 consecutive years, with $6.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Operating Leases rose 346.18% year-over-year to $6.0 million; the TTM figure through Apr 2026 stood at $6.0 million (up 346.18% YoY), while the FY2025 annual figure was $6.5 million, up 352.35% from the prior year.
- Operating Leases eased to $6.0 million in Q2 2026 per ENGN's latest filing, from $6.2 million in the prior quarter.
- Across five years, Operating Leases topped out at $6.7 million in Q3 2025 and bottomed at $1.3 million in Q1 2025.
- Historically, Operating Leases has averaged $3.4 million across 3 years, with a median of $1.6 million in 2024.
- Annual changes were most pronounced in 2025 — Operating Leases dropped 16.92% — and 2026, when it soared 367.47%.
- enGene Therapeutics' Operating Leases stood at $1.4 million in 2024, then jumped by 352.35% to $6.5 million in 2025, then retreated by 7.65% to $6.0 million in 2026.
- Business Quant data shows ENGN's Operating Leases at $6.0 million in Q2 2026, $6.2 million in Q1 2026, and $6.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 5.96 Mn |
| Jan 31, 2026 | 6.22 Mn |
| Oct 31, 2025 | 6.46 Mn |
| Jul 31, 2025 | 6.73 Mn |
| Apr 30, 2025 | 1.34 Mn |
| Jan 31, 2025 | 1.33 Mn |
| Oct 31, 2024 | 1.43 Mn |
| Jul 31, 2024 | 1.48 Mn |
| Apr 30, 2024 | 1.53 Mn |
| Jan 31, 2024 | 1.60 Mn |